Robyn Karnauskas
Stock Analyst at Truist Securities
(1.86)
# 3,230
Out of 4,983 analysts
181
Total ratings
41.77%
Success rate
-1.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRML Tourmaline Bio | Downgrades: Hold | $63 → $48 | $47.71 | +0.61% | 3 | Sep 10, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.77 | +109.64% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $273.09 | +9.12% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.34 | +40.27% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $81.09 | +35.65% | 11 | Jan 8, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,033 → $1,029 | $764.71 | +34.56% | 5 | Oct 31, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $110.86 | -25.13% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $216.26 | -2.89% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $2.02 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $143.68 | +136.64% | 17 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 | $1.71 | +1,420.47% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.36 | +414.71% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $575.06 | +97.37% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.61 | +521.12% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.70 | +233.33% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $14.18 | +62.20% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $15.29 | +213.93% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $11.75 | +325.53% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $391.36 | +29.80% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $23.90 | +50.63% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $59.69 | -58.12% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.99 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $53.94 | +159.55% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $4.42 | +678,633.03% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $0.95 | +636.30% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.47 | +280.10% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $23.05 | +1,288.29% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $9.33 | +60.77% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.43 | +19,667.44% | 1 | Oct 8, 2020 |
Tourmaline Bio
Sep 10, 2025
Downgrades: Hold
Price Target: $63 → $48
Current: $47.71
Upside: +0.61%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.77
Upside: +109.64%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $273.09
Upside: +9.12%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.34
Upside: +40.27%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $81.09
Upside: +35.65%
Eli Lilly and Company
Oct 31, 2024
Maintains: Buy
Price Target: $1,033 → $1,029
Current: $764.71
Upside: +34.56%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $110.86
Upside: -25.13%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $216.26
Upside: -2.89%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.02
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $143.68
Upside: +136.64%
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.71
Upside: +1,420.47%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.36
Upside: +414.71%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $575.06
Upside: +97.37%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.61
Upside: +521.12%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.70
Upside: +233.33%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $14.18
Upside: +62.20%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $15.29
Upside: +213.93%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $11.75
Upside: +325.53%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $391.36
Upside: +29.80%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $23.90
Upside: +50.63%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $59.69
Upside: -58.12%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.99
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $53.94
Upside: +159.55%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $4.42
Upside: +678,633.03%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $0.95
Upside: +636.30%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.47
Upside: +280.10%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $23.05
Upside: +1,288.29%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $9.33
Upside: +60.77%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.43
Upside: +19,667.44%